Pillars of growth

R&D

Heavy bet for R&D
as a future
growth engine

conocer +

R&D&i
R&D

Heavy bet on R&D
as a future
growth engine

find out more

R&D&i
Biosimilar de Enoxaparina

Biosimilars

A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.
 

find out more

Bemiparina

Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.
 

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures

+16%

Net profit of the "on-going business" in 2017

+7%

2017 Bemiparinsales in Spain

56 countries

Bemiparim international presence  with 22 international partners

4 plants

for manufacturing own and third-party products in Spain

€28,3Mn

of investment in R&D in 2017 Commitment to innovation

6 countries

Direct presence through subsidiaries  to market Enoxaparin

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors